Seven notes:
1. Fourth quarter revenue grew 0.5% year-over-year.
2. The company’s net income of $654 million decreased 45% year-over-year.
3. Medtronic’s neuroscience portfolio, which includes cranial and spinal technologies, specialty therapies and neuromodulation, saw $2.5 billion in the fourth quarter, an increase of 5.6% year-over-year.
4. The neuromodulation business saw $9 billion in total sales in fiscal year 2024, an increase of 5% year-over-year.
5. Full fiscal year sales for Medtronic were $32.4 billion, an increase of 3.6% year-over-year.
6. Medtronic’s total net income for fiscal year 2024 was $3.7 billion, a decrease of 2% year-over year.
7. Medtronic is projecting fiscal year 2025 revenue to increase 4% to 5% compared to fiscal year 2024.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
